PRTC vs. AUPH, PAHC, NRIX, SAGE, NUVB, WVE, PRAX, COGT, IRON, and ALXO
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Aurinia Pharmaceuticals (AUPH), Phibro Animal Health (PAHC), Nurix Therapeutics (NRIX), Sage Therapeutics (SAGE), Nuvation Bio (NUVB), Wave Life Sciences (WVE), Praxis Precision Medicines (PRAX), Cogent Biosciences (COGT), Disc Medicine (IRON), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical preparations" industry.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
PureTech Health has a net margin of 0.00% compared to PureTech Health's net margin of -32.69%. Aurinia Pharmaceuticals' return on equity of 0.00% beat PureTech Health's return on equity.
Aurinia Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Aurinia Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 73.61%. Given PureTech Health's higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than PureTech Health.
PureTech Health has lower revenue, but higher earnings than Aurinia Pharmaceuticals.
In the previous week, Aurinia Pharmaceuticals had 7 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Aurinia Pharmaceuticals and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.87 beat Aurinia Pharmaceuticals' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Aurinia Pharmaceuticals received 560 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 73.07% of users gave Aurinia Pharmaceuticals an outperform vote while only 38.89% of users gave PureTech Health an outperform vote.
Summary
Aurinia Pharmaceuticals beats PureTech Health on 9 of the 15 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
